| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 5.3K | 0.6% |
| Total Income | 5.3K | 0.4% |
| Expenditure | 4.1K | 2.7% |
| PBT | 1.2K | 6.8% |
| Net Profit | 1.0K | 11.5% |
| OPM | 16.43% | 1.60pp |
| NPM | 18.86% | 1.94pp |
| EPS | 10.18 | 12.5% |
Zydus Lifesciences Reports Q3 FY25 Revenue of Rs. 52,691 Mn, Net Profit of Rs. 10,235 Mn
05 Feb 2025 · 5 Feb 2025, 06:03 pm
Summary
Zydus Lifesciences Ltd. announced its unaudited consolidated financial results for the quarter and nine months ended December 31, 2024. The company reported a revenue from operations of Rs. 52,691 mn for Q3 FY25, a 17% increase over the same period last year. The net profit for the quarter was Rs. 10,235 mn, a 30% increase over Q3 FY24.
Key Highlights
- 1
Revenue from operations at Rs. 52,691 mn, up 17% YoY
- 2
Net Profit at Rs. 10,235 mn, up 30% YoY
- 3
R&D investments for the quarter at Rs. 5,031 mn (9.5% of revenues)
- 4
EBITDA for the quarter at Rs. 13,876 mn, up 26% YoY
- 5
Net Debt to Equity ratio as on December 31, 2024, at -0.14x
Management Comments
Dr. Sharvil Patel
Managing Director - Zydus Lifesciences Limited
We are pleased with the sustained growth momentum across our key businesses that has driven our Q3 performance. Our robust product portfolio execution in the US, market share gain in focused therapy segments and brands in India, and strategic leveraging of our global portfolio in International Markets position us well for future growth. We are on track to achieve our fiscal year 2025 goal of double-digit growth across our key businesses, coupled with improved profitability. Looking ahead, we are strategically building growth levers to ensure sustained success, with patient centricity and quality at the core of our operations.
Informational and educational content only. Not investment advice.